{"id":"W2898560392","doi":"10.1093/annonc/mdy284.054","title":"Phase III double-blind study evaluating lens opacifications (LO) in patients with nonmetastatic prostate cancer (PCa) receiving denosumab (Dmab) for bone loss due to androgen deprivation therapy (ADT)","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Connexins and lens biology","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"DOD Prostate Cancer Research Program; Weill Cornell Medical College; Cilag; Astellas Pharma; National Cancer Institute; Genomic Health; Memorial Sloan-Kettering Cancer Center; Prostate Cancer Foundation; Eli Lilly and Company; U.S. Department of Defense; Sanofi; Abbott Laboratories; National Institutes of Health; London Health Sciences Centre; Amgen","keywords":"Medicine; Androgen deprivation therapy; Prostate cancer; Clinical endpoint; Denosumab; Urology; Randomized controlled trial; Placebo; Internal medicine; Surgery; Osteoporosis; Cancer; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001773695,0.001820985,0.003648914,0.0003831842,0.0005602006,0.001111595,0.001218992,0.001818549,0.008527607],"category_scores_gemma":[0.001687349,0.0009513018,0.001715644,0.0005788868,0.001135878,0.0009576716,0.0004165805,0.00328249,0.001581115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006735213,"about_ca_system_score_gemma":0.001990116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001281352,"about_ca_topic_score_gemma":0.003835587,"domain_scores_codex":[0.9994442,0.0002693064,0.00003395932,0.0001258658,0.00004488123,0.00008178497],"domain_scores_gemma":[0.9987914,0.0002812974,0.0002588899,0.0001089428,0.0001322101,0.000427377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9599561,0.02046541,0.0006501008,0.000921729,0.001096889,0.00003001974,0.00005847256,0.0003137947,0.003686212,0.00008055288,0.001177099,0.01156363],"study_design_scores_gemma":[0.94293,0.05483069,0.00110346,0.00002179518,0.0002016387,0.00001640668,0.00001480217,0.0001853408,0.0002137736,0.00007904958,0.0003951495,0.000007827886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9659451,0.007896349,0.001808517,0.001029576,0.0009985885,0.01418789,0.003235802,0.0004249892,0.004473223],"genre_scores_gemma":[0.9719751,0.003613518,0.002323636,0.00181643,0.0004545615,0.0121662,0.001742741,0.00004869336,0.005859127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008527607,"threshold_uncertainty_score":0.02852768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1241160300248892,"score_gpt":0.4348519189209851,"score_spread":0.3107358888960959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}